Presentations From prIME Masterclass in NETs - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations From prIME Masterclass in NETs

Multidisciplinary Perspectives on the Treatment of Neuroendocrine Tumors

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

View downloadable slides for updates about the latest advances and emerging strategies in the management of neuroendocrine tumors (NETs), including epidemiology, clinical characteristics, natural history, pathophysiology, and current and emerging treatment strategies for patients with functioning and nonfunctioning NETs.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Dec 6, 2019

Expiration Date

Dec 6, 2020

SESSION I: Biology, Pathology, and Prognosis

Pathology workshop

Featured Expert: Jean-Yves Scoazec, MD, PhD

Intracellular targeting of neuroendocrine tumors

Featured Expert: Justo Castaño, MS, PhD

Literature review: Basic science—What is new in 2019?

Featured Expert: Chrissie Thirlwell, BSc, MD, PhD, FRCP

Challenges in NET management: How does the expert do it?

Small bowel resection

Featured Expert: Reza Kianmanesh, MD, PhD

Follow-up: How long and how best?

Featured Expert: Philippe Ruszniewski, MD

Metabolic complications of neuroendocrine neoplasia (NEN)

Featured Expert: Wouter de Herder, MD, PhD

Screening and surveillance in multiple endocrine neoplasia type 1 (MEN 1)

Featured Expert: Gerlof Valk, MD, PhD

SESSION II: Workshops

Peptide receptor radionucleotide therapy (PRRT)

Featured Expert: Tessa Brabander, MD, PhD

Functional imaging for NETs

Featured Expert: Prakash Manoharan, MBChB, MRCP, FRCR

Interventional radiology

Featured Expert: Maxime Ronot, MD, PhD

Genomics in clinical decision making for NET management

Featured Expert: Eva Tiensuu Janson, MD, PhD

SESSION III: Therapy and Patient Care

Keynote lecture—Immunotherapy: Can we apply to NETs?

Featured Expert: Wolf Fridman, MD, PhD

Keynote lecture—Communicating risk and uncertainty in NETs

Featured Expert: Lesley Fallowfield, DBE, FMedSci, Dphil, BSc

Literature review: Clinical—what is new in 2019?

Featured Expert: Christos Toumpanakis, MD, PhD, FRCP

SESSION IV: Future Perspectives and prIME Points™

Current knowledge and future perspectives on NET treatment

Featured Expert: Juan Valle, MBChB, MSc, FRCP

prIME Points™

This educational activity is designed for European medical oncologists, endocrinologists, gastroenterologists, nuclear medicine specialists, and other healthcare providers involved and/or interested in the management of patients with neuroendocrine tumors (NETs).

After successful completion of this educational activity, participants should be able to:

  • Describe the epidemiology, clinical characteristics, and natural history of NETs
  • Understand the cellular pathways of relevance in NETs and the role of molecular pathology in patient management
  • Select appropriate therapy from the increasing range of therapeutic options available for first and subsequent lines of treatment
  • Identify the potential for novel therapeutic strategies in the treatment of NETs

This educational activity is supported by Ipsen.

Independent Medical Education (IME)

This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME, a Medscape Oncology Company.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Tessa Brabander, MD, PhD, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Advanced Accelerator Applications; Novartis Pharmaceuticals Corporation
  • Served as a speaker or a member of a speakers bureau for: Advanced Accelerator Applications; Novartis Pharmaceuticals Corporation
  • Received grants for clinical research from Advanced Accelerator Applications; Novartis Pharmaceuticals Corporation

Jaume Capdevila, MD, PhD, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Advanced Accelerator Applications; Amgen Inc.; Bayer HealthCare; Eisai Inc.; Exelixis; Ipsen; Merck Serono; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi
  • Served as a speaker or a member of a speakers bureau for: Advanced Accelerator Applications; Amgen; Bayer HealthCare; Amgen Inc.; Eisai Inc.; Exelixis; Ipsen; Merck Serono; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi
  • Received grants for clinical research from: Advanced Accelerator Applications; AstraZeneca; Eisai Inc.; Ipsen; Novartis; Pfizer

Justo Castaño, MS, PhD, has disclosed the following relevant financial relationships:

  • Served as a speaker or a member of a speakers bureau for: IPSEN; Novartis Pharmaceuticals Corporation
  • Received grants for clinical research from: IPSEN; Novartis Pharmaceuticals Corporation

Robert Coleman, MD, FRCP, FRCPE, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Amgen; Astellas
  • Other: InBiomotion (Patent Holder and Chair of Scientific Board)

Wouter de Herder, MD, PhD, has disclosed the following relevant financial relationships:

  • Served as a speaker or a member of a speakers bureau for: Adacap (AAA); Ipsen; Novartis Pharmaceuticals Corporation; Pfizer Inc.
  • Received grants for clinical research from: Ipsen

Lesley Fallowfield, DBE, FMedSci, Dphil, BSc, has disclosed following relevant financial relationships:

  • Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Genomic Health; Voluntis
  • Served as a speaker or a member of a speakers bureau for: Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.
  • Received grants for clinical research from: NanoString

Wolf Fridman, MD, PhD, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Adaptimmune; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Catalym; Immunocore; Ipsen; Novartis Pharmaceuticals Corporation; Oxford Biotherapeutics; Pierre Fabre; SERVIER
  • Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb
  • Owns stock, stock options, or bonds from: OSE Immunotherapeutics

Reza Kianmanesh, MD, PhD, has disclosed no relevant financial relationships.

Prakash Manoharan, MBChB, MRCP, FRCR, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: AAA Pharmaceuticals; AML; Ipsen; Novartis Pharmaceuticals Corporation; Siemens Healthcare Diagnostics Inc
  • Served as a speaker or a member of a speakers bureau for: AML; AAA Pharmaceuticals
  • Received grants for clinical research from: (Click here to enter…)

Dermot O’Toole, MD, FRCPI, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: AstraZeneca; Ipsen; Novartis Pharmaceuticals Corporation; Wyeth Lederle
  • Served as a speaker or a member of a speakers bureau for: Ipsen; Novartis Pharmaceuticals Corporation
  • Received grants for clinical research from: Ipsen; Novartis Pharmaceuticals Corporation

Marianne Pavel, MD, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: AAA Pharmaceutical Inc.; Ipsen; Lexicon Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
  • Served as a speaker or a member of a speakers bureau for: AAA Pharmaceutical Inc.; Ipsen; Lexicon Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
  • Received grants for clinical research from: Ipsen; Novartis

Maxime Ronot, MD, PhD, has disclosed no relevant financial relationships.

Philippe Ruszniewski, MD, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Advanced Accelerator Applications; Ipsen; Isotopen Technologien München AG; Novartis
  • Received grants for clinical research from: Advanced Accelerator Applications; Ipsen; Isotopen Technologien München AG

Jean-Yves Scoazec, MD, PhD, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Bayer HealthCare; Ipsen; Novartis Pharmaceuticals Corporation; Pfizer Inc.
  • Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation

Chrissie Thirlwell, BSc, MD, PhD, FRCP, has disclosed no relevant financial relationships.

Eva Tiensuu Janson, MD, PhD, has disclosed no relevant financial relationships.

Christos ToumpanakisMD, PhD, FRCP, FEBGH, AGAF, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Advanced Accelerator Applications; Ipsen; Novartis Pharmaceuticals Corporation
  • Served as a speaker or a member of a speakers bureau for: Advanced Accelerator Applications; Ipsen; Novartis Pharmaceuticals Corporation
  • Received grants for clinical research from: Advanced Accelerator Applications; Ipsen; Novartis Pharmaceuticals Corporation

Gerlof Valk, MD, PhD, has disclosed the following relevant financial relationships:

  • Received grants for clinical research from: Ipsen

Juan Valle, MB ChB, MSc, FRCP, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Ipsen; Imaging Equipment Ltd; Novartis Pharmaceuticals Corporation
  • Served as a speaker or a member of a speakers bureau for: Ipsen; Imaging Equipment Ltd; Novartis Pharmaceuticals Corporation

 

The employees of prIME, a Medscape Oncology Company have disclosed no relevant financial relationships.

Content Reviewers
Amy Bernard, MS, BSN, RN-BC, CHCP
Director, Accreditation and Compliance
Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Esther Nyarko, PharmD
Associate Director, Accreditation
Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.